Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$23 Mln
P/E Ratio
--
P/B Ratio
0.38
Industry P/E
--
Debt to Equity
0.52
ROE
-0.77 %
ROCE
-50.52 %
Div. Yield
0 %
Book Value
1.05
EPS
-0.78
CFO
$-189.58 Mln
EBITDA
$-189.99 Mln
Net Profit
$-195.97 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Elevation Oncology Inc (ELEV)
| -34.71 | 22.39 | -45.18 | -90.93 | -45.98 | -- | -- |
|
BSE Sensex
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Elevation Oncology Inc (ELEV)
| 4.73 | -43.47 | -84.22 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.79 | 9,808.03 | 20.22 | 23.13 | |
| 289.41 | 8,956.09 | 22.08 | 58.42 | |
| 26.79 | 9,559.25 | -- | -28.77 | |
| 103.51 | 10,030.35 | 30.81 | 14.16 |
Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. It's lead candidate is EO-3021, an antibody-drug... conjugate (ADC) comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload that is in Phase 1 clinical trial as a monotherapy and in combinations with dostarlimab, a PD-1 inhibitor, and ramucirumab, a VEGFR2 inhibitor, in patients with advanced, unresectable, or metastatic gastric/gastroesophageal junction solid tumors. The company is also developing EO-1022, an ADC containing seribantumab, a fully human immunoglobulin G2 (IgG2) anti-HER3 mAb, and an MMAE payload, with glycan site-specific conjugation for the treatment of patients with HER3-expressing solid tumors, including breast cancer, non-small cell lung cancer, and other solid tumors. It has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021 for the treatment of cancer. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts. Address: 101 Federal Street, Boston, MA, United States, 02110 Read more
Chief Scientific Officer
Dr. David Dornan Ph.D.
Chief Scientific Officer
Dr. David Dornan Ph.D.
Headquarters
Boston, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Elevation Oncology Inc (ELEV) stood at $ 96 Mln as on 31-Dec-24
The share price of Elevation Oncology Inc (ELEV) is $0.37 (NASDAQ) as of 23-Apr-2025 13:42 EDT. Elevation Oncology Inc (ELEV) has given a return of -45.98% in the last 3 years.
Elevation Oncology Inc (ELEV) has a market capitalisation of $ 23 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Elevation Oncology Inc (ELEV) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Elevation Oncology Inc (ELEV) and enter the required number of quantities and click on buy to purchase the shares of Elevation Oncology Inc (ELEV).
Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. It's lead candidate is EO-3021, an antibody-drug conjugate (ADC) comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload that is in Phase 1 clinical trial as a monotherapy and in combinations with dostarlimab, a PD-1 inhibitor, and ramucirumab, a VEGFR2 inhibitor, in patients with advanced, unresectable, or metastatic gastric/gastroesophageal junction solid tumors. The company is also developing EO-1022, an ADC containing seribantumab, a fully human immunoglobulin G2 (IgG2) anti-HER3 mAb, and an MMAE payload, with glycan site-specific conjugation for the treatment of patients with HER3-expressing solid tumors, including breast cancer, non-small cell lung cancer, and other solid tumors. It has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021 for the treatment of cancer. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts. Address: 101 Federal Street, Boston, MA, United States, 02110
The CEO & director of Dr. David Dornan Ph.D.. is Elevation Oncology Inc (ELEV), and CFO & Sr. VP is Dr. David Dornan Ph.D..
There is no promoter pledging in Elevation Oncology Inc (ELEV).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Elevation Oncology Inc (ELEV) | Ratios |
|---|---|
|
Return on equity(%)
|
-77.48
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Elevation Oncology Inc (ELEV) was $0 Mln.
$0.00
(
